https://doi.org/10.48047/AFJBS.6.15.2024.12114-12135

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

A Review on Pathophysiology, Diagnosis and Treatment of Alzheimer's disease.

Dr. Sonali Sonulkar*[1], Dr. Archana Gorle[1], Dr. Suvarna Phadtare[3], Mrs. Vaishali Sorte[1], Mr. Khush Jain[2], Ms. Fariah Rizwani[2], Mr. Mohammad Ali[1]

[1]NCRD'S Sterling Institute of Pharmacy, Nerul, Navi Mumbai
[2]D.Y.Patil University School of Pharmacy, Nerul, Navi Mumbai
Bharti Vidyapeeth College of Pharmacy, Navi Mumbai

***Address for correspondence:**Dr. Sonali Sonulkar
Associate Professor
NCRD's Sterling Institute of Pharmacy, Nerul Navi-Mumbai- 400706, Maharashtra, India.
Email I'd: sonaliaskarkar@gmail.com
Contact no. +91-9967116009

Volume 6, Issue 15, Sep 2024

Received: 15 July 2024

Accepted: 25 Aug 2024

Published: 25 Sep 2024

doi: 10.48047/AFJBS.6.15.2024.12114-12135

Abstract

Background: An Alzheimer's disease (AD) is generally concerned with outer settling of amyloid-β which is in the state of neuritis and diffused plaques and it also shows the existence of neuropil threads and intraneuronal neurofibrillary tangles inside dystrophic neuritis which consisted of aggregated hyper phosphorylated tau protein. **Main body of the abstract:** Dementia is a disorder associated with AD is in relation with the onset of extensive and revolutionary incapacity for the duration of the sickness direction with demise an inevitable outcome, typically going on for period of [5-12 years] of symptom onset. There's a dire want for ailment editing remedies which may also stop or sluggish fee of ailment progression, however unluckily none are presently available. The statistical data of medical and pharmaceutical improvement for AD has been afflicted to medical trial failures. Nevertheless, enormous steps have been taken in recent decades in deeply studying the key factors for causing pathobiology of Alzheimer's disease. However, the therapeutic pipeline of Alzheimer's disease has confronted many difficulties and few pharma-tech groups have neglected the drug improvement in Alzheimer's disease.

Short conclusion: Novel drug delivery therapeutic methods for AD has been ignored and nevertheless being positively formulated and evaluated. This review article specifies about current research advances in the pathobiology of Alzheimer's disease and also summarizes the various treatment strategies and opportunities and challenges faced while being on the road in development of a new therapeutic treatment.



Fig.No.1: Alzheimer's disease distribution study carried throughout the world based on age and population for both the sexes, 2016

Background:-

Out of the about 50 million humans globally live with dementia, between 60% and 70% are estimated to have Alzheimer's disease. **India** has close to 4 million people who are surveyed to be affected from **Alzheimer's** and its closely related disorders[1]**.**



Fig.No.2: Prevalence study done at Global levels for Alzheimer's disease and other closely related disorders in both the sexes, 2016

Alzheimer's disorder is a modern neurologic ailment that results in brain atrophy and degeneration of neurotic brain cells and tissues. Alzheimer's disease mainly causes dementia[2]. The most targeted patients are of age 65, which constitutes to [LOAD – late onset Alzheimer's disease], and there's 5% instances of getting Alzheimer's disease is patients [EOAD – early onset Alzheimer's disease[3]]. In recent studies, it is stated that due to dementia deaths of patients have shot up by 148%. At Global levels, dementia stood as 5th largest death causing disease, shown in 2016 study reports. Dementia precipitated to 28.8 million DALYs, to make it a 23rd biggest motive of DALYs in 2016. Over the past many decades, it has increased to 6·3% DALYs (23·9 million DALYs) [4, 5, 6].



Fig.No.3: Global study estimating YLLs and YLDs caused due to Alzheimer's disease and other dementias

Etiological study of Alzheimer's disease:-

Alzheimer's disease leads to continuous cognitive degradation and it is characterised by neuro-fibrillary tangles and β-amyloid deposits in the cortical and sub-cortical regions of brain. Most of the patients with Alzheimer's disease are sporadic and LOAD (≥ 65 years). Predicting the risk of AD is preliminary done by analyzing age. Out of total cases, 5 to 15% of cases accounts for familial relations; out of which half the cases are diagnosed with EOAD (< 65 years) and are mostly in connection to genetic mutations. Minimally 5 awesome genetic loci are positioned on chromosomes 21, 19, 14, 12 and 1 showing its effect on initiation and progression of Alzheimer's disease[7].

Genetic mutations occurring at presenilin I, amyloid precursor protein and presenilin II leads to autosomal variants of Alzheimer's disease. The patients affected with AD have altered processing of amyloid precursor protein which leads to deposition and aggregation of β-amyloid cell[8]. β-amyloid is the major component present in senile plaques, that includes astrocytes, degenerated axonal or dendritic processes. β-amyloid alters phosphatise and kinase activities which ultimately leads to formation of neuro-fibrillary tangles and hyper-

phosphorylation of *tau*.



Fig.No.4: Diagrammatic comparison of Healthy and Alzheimer Diseased Brain

Genetic mutation encompasses the Apolioprotein E that shows an effect on cytoskeleton integrity, β-amyloid deposition and effectivity of neuronal repair. Patients with two E-4 alleles have increased risks for AD and have low risk in patients with E-2 allele. Patients with two E-4 alleles develop AD by the age of 75. There are many other risk factors associated in developing Alzheimer's disease are drinking alcohol, smoking and also post-treatment effects of disorders like diabetes and hypertension[8]. In superior degrees of the disease, problems from extreme loss of neurotic characteristic — such as dehydration, malnutrition or contamination - results in loss of life[9, 10].

Main Text:

Pathophysiology of Alzheimer's disease:-

The most common causes of pathogenesis of AD are as follows[11]:-

1. Intracellular neuro-fibrillary tangles (paired helical filaments).
2. (Apoe) Apo-lipoprotein - strongest genetic factor for LOAD (Late Onset AD).

3. Extracellular β-amyloid deposits (in senile plaques).

1.) Intracellular neuro-fibrillary tangles (paired helical filaments):- A microtubule-associated protein named Tau is part of this cause; there are many insoluble filaments which accumulate as a neuro-fibrillary tangles resulting in Alzheimer's disorder (AD). A massive physique of proof suggested that hyperphosphorylation of Tau results from perturbation process of cellular signaling, often thru dispaired in the things to do of distinct protein phosphatises and kinases. In Alzheimer, it seems that (Aß) performs a pivotal position in activating this imbalance[12, 13]. Under wholesome stipulations tau is accountable for structural balance of microtubule, then again due to hyperphosphorylation it purpose dismantle of such tubule.



Fig.No.5: Diagrammatic representation of comparison of the healthy and diseased Brain

Tau protein needs to face several after-translational changes, which include acetylation, nitration, phosphorylation, O-GlcNAcylation, ubiquitination, glycation, truncation and SUMOylation inside the body. Acetylation process of Tau has preved that it limits degeneration of phosphorylated tau; expands tau pathology[14] however has additionally been proven to inhibit tau phosphorylation at positive residues and restrict similarly aggregation[15]. Acetylation process of Tau has additionally proved till end results in axon preliminary phase cyto-skeletal instability accompanied by using mispositioning of tau to somato-dendritic compartment[16]. O-GlcNAc amendment of tau inhibits poisonous self-assembly[17]

2.) Apo-lipoprotein - strongest genetic factor for LOAD (Late Onset AD):- Apo-E is a type of Apo-lipoprotein which foremost characteristics to act as a binder protein to lipoprotein particles and it take part in circulation of lipids to their specific goal regions. ApoE protein is to be expressed at the best possible degrees in the brain and liver. The APOE protein has three frequent alleles encoded as three protein iso-forms as ApoE4, ApoE3 and ApoE2. A single inherited reproduction of the APOE ε4 allele will increase hazard of growing LOAD by means of about 3-4 fold, whilst two inherited copies will increase threat by way of ~12-fold[18]. Inheritance of the APOE ε2 allele is protective.

ApoE probably regulates AD hazard in giant section by means of outcomes on amyloid pathology[19]. ApoE immediately binds to Aβ existing in plaques[20]. Apo-E inhibits clearance and/or promotes Aβ seeding[21, 22, 23, and 24].

Genotype	**E2/E2**	**E2/E3**	**E2/E4**	**E3/E3**	**E3/E4**	**E4/E4**
Disease Risk	40% less likely	40% less likely	2.6 times more likely	Average risk	3.2 times more likely	14.9 times more likely

Table.No.1: Tabular representation of the risk of developing disease

3.) Extracellular β-amyloid deposits - in senile plaques: - β-amyloid is predominantly produced in endosomes, its launch from neurons is regulated by route of synapsis[9], each pre synaptically[10] and submit synaptically[11]. Aβ peptide used to be first recognized as the major constituent of meningo-vascular amyloid in 1984 and due to this fact as the major constituent in amyloid neuritic plaques[7]. β-amyloid is one of the proteolytic fragment of the large APP-amyloid precursor protein. γ-secretase can be used to cleave β-CTF , it has varied length; by and large forty AA – amino acid, lengthy Aβ40 peptide and a two (AA) longer peptide - Aβ42, are generated. In view of the fact that it is multiplied hydrophobicity and due to which peptide Aβ42 is in a position in constructing aggregation which is the principal variant of β-amyloid in senile plaques[12].



Fig.No.6: Representation of formation of α-β Amyloid Protein

Recent advances in study of pathophysiology of Alzheimer disease:-

Herpes virus and AD Pathogenesis: - Multiple ultra-modern lookup have resuscitated interest in a well established theory that would possibly additionally be a fundamental infection basis for Alzheimer's disease. Studies have reported that the existence of herpes virus in brains of victims with Alzheimer's, properly as internal amyloid plaques[25, 26, 27 and 28]. A present day model driven molecular neighbourhood assessment of preclinical study of AD brain diagnosed with a neighbourhood genes mentioned to be enhanced for genes with viral susceptibility. Further analytical studies conducted on AD brain samples placed Herpes Simplex Virus (HSV)-1 DNA and removable Human Herpes Virus (HHV)-6 in different units, and recognized various assumed viral and host interactions which alters gene networks that are relevant to AD diagnosis, collectively with APP processing and innate immunity[29].

Two contemporary Taiwanese-based research studies showed the affiliation of Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) and illness along chances of having dementia. One report stated that having danger of occurrence in 3-times increase in dementia, in patients with age group more than 50 followed by a latest HSV infection. This chance used to be nearly eradicated in victims that acquired anti herpetic treatment[30]. A 2nd learn about located out about established a very average accelerated hazard of evolving of dementia after infection with ZSV. Afresh, a huge downfall in dementia hazard was once as soon as located in victims that got anti-herpetic remedy[31] (HR 0.47). The penalties of these studies will favour to get replicate, preferably in a huge manageable observational unit study, until now than getting HSV and HHV illness as a real threat aspect for AD and its closely connected dementias. Additionally, modern-day locate out about suggests that periodontal infections can additionally make contributions to AD pathogenesis[7].

Innate Humanity and AD pathogenesis: - There is growing proof that interactions between the CNS natural immune system may also regulate AD in origination and its development. Several researches have described the constitution of the intestinal micro biota in each methods of amyloidosis (APP/PS1), also in human patients diagnosed with dementia due to Alzheimer's disease and has discovered extensive variations in the typically rich variety of microbial variants which are in relation to non-demented manipulate participants and WT animals[29, 30 and 31]. Indeed, one find out about proven that APP/PS1ΔE9 mice which is chronically given a cocktail dose of antibiotics to regulate micro-biome constitution had appreciably decreased. Initiation of the natural immune system without doubt functions in AD's pathophysiology. However, facts concerning function of triggered microglia present in animal fashions advocate per chance divergent consequences relying on sickness context.

Sleep impairment and AD pathogenesis: - Sleep impairment leads to despaired concentration, working reminiscence, and attention might additionally have an impact on improvement of underlying AD pathology. In a current learn about of partial sleep destitution that lasts 5-8 days, with no modifications in AD-CSF biomarkers had been cited even though

that learn about did now not alter the extent of slow-wave sleep[32]. Two principal methods that are estimated as to how sleep destitution or extended wakefulness will increase extracellular β-amyloid in the brain. Studies recommended that lymphatic clearance is tedious and slow for the duration of wakefulness vs. Sleep[33, 34]. Increased synaptic β-amyloid launch due to expanded neuronal metabolism/activity in the course of wakefulness vs. sleep is any other mechanism Increased synaptic and community exercise has been earlier proven to regulate launch of extracellular β-amyloid and tau from neurons[35, 36, 37 and 38]. With researched learn about with recombinant artificial tau fibrils, animals with sleep disturbance had greater good sized tau spreading then in non-sleep dismantle animal. In summary, Sleep disturbance in human beings can additionally accountable for growing AD. Furthermore, Sleep impairment can stimulate the expand degree of β-amyloid plague and tau formation and can similarly extend the complication. Sleep impairment is additionally accountable for degeneration of Genius functions[39].

Diagnosis of AD: - It's necessary to notice that Alzheimer's ailment can be definitively identified solely after death, via linking scientific measures with an examination of Genius tissue in an autopsy. Patients having household records of dementia are extra inclined to strengthen AD. And household records perform a essential function in analysis of AD. Although the all clear analysis take a look at aren't accessible for analysis of AD, however Brain imagining and CSF take a look at useful resource a lot in prognosis of sickness in sufferers even earlier than the preliminary signs occurs[40]. But these invasive take a look at are expansive. For e.g.: A common of 8000-14000 Rupees is required for PET scans. Even after being so pricey these take a look at keep no credibility in pursuits care of tens of millions of humans struggling from the most frequent neurodegenerative disorder. In truth such check are solely beneficial in lookup settings.

But latest research on the cost of PET beta-amyloid intelligence scans, supported by using the Centres for Medicare & Medicaid Services, have proven that training "dementia expert" medical doctors misdiagnose Alzheimer's in about 50 percentage of instances and alternate their administration and therapy of sufferers almost 70 percentage of the time when this check is used. A less expensive blood test, protected through insurance, which can be carried out in any scientific setting, would have a large have an effect on sufferers and their caregivers. We want similar tests—preferably blood tests—to assist diagnose Alzheimer's and consider treatments. This will useful resource us in making scientific trials extra rigorous, low priced and efficient, will speed up drug improvement and will enhance medical care by means of imparting get right of entry to correct diagnoses[41].

An initiative known as the Diagnostics Accelerator, launched on July 2018 underneath the auspices of the Alzheimer's Drug Discovery Foundation, ambitions to improve novel biomarkers from blood and handy fluids and tissue. Such markers especially tied to Alzheimer's or different varieties of dementia will enable us to predict extra precisely which cure and prevention strategies[16].

Advances in diagnosis of Alzheimer disease:-

1) An effective blood test: - Amyloid build-up is a key pathological function of Alzheimer's, and deciding the diploma to which someone's Genius is riddled with the molecule is necessary for designing superb medical trials. The new findings advise an easy blood check can precisely predict ranges of a protein referred to as amyloid beta in the intelligence that

starts acting early in the route of the ailment earlier than signs and symptoms appear[42]. Senior learn about creator Katsuhiko Yanagisawa, director regular of the National Centre for Geriatrics and Gerontology in Japan, is satisfied that sufficient amyloid penetrates the blood–brain barrier to make its way into the bloodstream to be a beneficial measure of cognitive function. To measure bits of amyloid coursing via the bloodstream, Yanagisawa and colleagues used an approach referred to as immunoprecipitation with mass spectrometry, which deploys antibodies to bind and become aware of proteins. The learn about protected 121 humans from Japan and 252 from Australia, and each agencies concerned humans with everyday talent function, moderate cognitive impairment and Alzheimer's. They observed the quantity of amyloid current in the blood correlated with the diploma of cognitive problems. Blood amyloid ranges additionally correlated with findings in the identical sufferers from PET scans and spinal fluid measures[43]. Emory University neurologist William Hu studies says "The findings are promising as dependable blood biomarkers can lead to early detection with an exceptionally straightforward method and decrease costs. Blood exams would be especially useful in figuring out sufferers for trials of viable tablets that should be most high quality lengthy earlier than the first symptom of cognitive decline[14].

2) C2N tests for AD: - C2N is conducting the PARIS Study, a two-phase pivotal medical trial evaluating the scientific diagnostic overall performance of its take a look at in humans at excessive hazard for Alzheimer's disease[44]. Last fall, a blood take a look at developed with the aid of C2N Diagnostics grew in becoming accessible to large population of U.S. as an events lab test that regulates under the CMS and CLIA program. The C2N test, known as Precivity AD, makes use of an analytic approach recognized as a [MS - mass spectrometry] to notice proteins like β-amyloid. It accumulates in plaque form as seen on intelligence scan many years earlier than an affected person notices reminiscence issues. As plaque formation constructs in the CNS area, ranges of β-amyloid reduces in the neighbouring fluids. Such adjustments are collected from spinal fluid samples and from blood. Precivity-AD is the first most blood that takes a look at for AD to be qualified for tremendous use and should allow early identification of the main neuronal degenerative disorder. Results of these studies showed a chance rating that displays the probability of a β-amyloid-positive intelligence scans that can be measured with the use of a registered protocol that accommodates the patient's sex, age, body parameters, etc. And also the measurement of β-amyloid protein and a protein that is referred to as Apo-lipoprotein E, further recognised as the main cause of Alzheimer's sickness.
Some clinical stipulations can have an impact on the ranges of blood proteins, perhaps skewing take a look at results[45]. "If anyone has persistent kidney disease, that can have an effect on the clearance of proteins," Mielke says. "Individuals with a excessive physique mass index have a tendency to have greater blood volume, so that ought to decrease protein levels."

Therapeutic strategies for Alzheimer's disease:-

Despite of sizeable efforts and techniques via the enterprise and the builders, there stays no tremendous remedy today[46]. There are presently 4 FDA authorised medicines for the administration of cognitive impairment and dysfunction in international things to do in symptomatic AD. These encompass three cholinesterase inhibitors rivastigmine, donepezil

and galantamine an uncompetitive NMDA receptor modulator. There was once no improvement in subject of medication for Alzheimer in previous sixteen years. Experts predict that it might also be due to the fact of much less quantity of statistics reachable on etiology of disease. Whereas some even consider that the reason wanted for the volunteers to qualify for the scientific trials hampers drug improvement programme. Various failed merchandise in latest years even demotivate industrialist from working on improvement for the remedy of the disease. Most of the pills used in the scientific trial are for the slight to average AD symptoms. As referred to beforehand in case of Alzheimer disorder that agglomeration of amyloid protein begins earlier than 15-20 years from the first symptom[47]. This is the superior stage of organic disorder with recognize to pathogenesis of disease. The modern AD scientific pipeline has over one hundred one-of-a-kind compounds presently being examined in quite a number phases of medical trials[48].

SR.NO	STUDY NAME	DRUG TYPE	SYMPTOMS	IDENTIFIER
1	Prednisone[49]	Compact molecule	Gentle to benign - AD	https://clinicaltrials.gov
2	Bapinezumab[50]	Monoclonal antibody-MA	Gentle to benign - AD	https://clinicaltrials.gov
3	Nilvadipine[51]	Compact molecule	Gentle to benign - AD	https://clinicaltrials.gov
4	Solanezumab (EXPEDITION-1, 2 and 3)[52]	Monoclonal antibody-MA	Gentle to benign - AD	https://clinicaltrials.gov
5	Naproxen, celecoxib (ADAPT study)[53]	Compact molecule	Prevention study	https://clinicaltrials.gov
6	Crenezumab (CREAD-1/2)[54]	Monoclonal antibody-MA	Gentle to benign - AD with β-amyloid as positive biomarkers	https://clinicaltrials.gov
7	Indomethacin[55]	Compact molecule	Gentle to benign - AD	https://clinicaltrials.gov
8	Dimebon[56]	Compact molecule	Gentle to benign - AD	https://clinicaltrials.gov
9	Aducanumab (ENGAGE; EMERGE)[57]	Monoclonal antibody-MA	Gentle AD	https://clinicaltrials.gov
10	Idalopirdine (STARBEAM)[58]	Compact molecule	Gentle to benign - AD	https://clinicaltrials.gov
11	AN-1792[59]	Aβ42 immunogen	Gentle to benign - AD	https://clinicaltrials.gov
12	Intepirdine[60]	Compact molecule	Gentle to benign - AD	https://clinicaltrials.gov
13	Semagacestat (IDENTITY-1/2)[61]	Compact molecule	Gentle to benign - AD	https://clinicaltrials.gov
14	Tarenflurbil[62]	Compact molecule	Gentle AD	https://clinicaltrials.gov
15	Verubecestat (APECS)[63]	Compact molecule	Gentle AD	https://clinicaltrials.gov
16	CNP520 (Umibecestat) (API Generation)[64]	Compact molecule	APOE ε4/ε4 carriers	https://clinicaltrials.gov
17	Atabecestat[65]	Compact molecule	B- amyloid, normal cognition	https://clinicaltrials.gov
18	Lanabecestat (AMARANTH; DAYBREAK-ALZ)	Compact molecule	Gentle to benign - AD	https://clinicaltrials.gov

Table.No.2: Therapeutic strategies for Alzheimer's disease

Q. Can symptomatic treatment be used to treat AD?

- Yes, Based on the observations, trails and current frontline treatment it can be concluded that symptomatic treatment has found to be very effective[66]. Various Symptomatic treatments are already used to relief patients from symptomatic development of the disease. Based on the above mentioned pathogenesis of the disease various treatment are used which include the following.

SR.NO.	NAME	TARGETS	EFFECTS
1	Donepezil	Cholinesterase inhibitor	Blocks acetylcholinesterace enzyme
2	Rivastigmine	Cholinesterase inhibitor	Blocks acetylcholinesterace enzyme
3	Galantamine	Cholinesterase inhibitor	Blocks acetylcholinesterace enzyme
4	Memantine (Namenda)	NMDA receptor antagonist	Blocks glutamate neurotransmitter and improves learning and memory
5	Donepezil and Memantine	Cholinesterase inhibitor and NMDA receptor antagonist	Blocks acetylcholinesterace enzyme and glutamate neurotransmitters.

Table.No.3: Summary of approved drugs for the treatment of Alzheimer's disease

Disease treatment: - A unique finds out about on pathogenesis clam that development of the ailment can be stopped if the elements contributing to the improvement of the sickness can be stopped[67]. Under the title of pathogenesis of sickness a number of elements contributing to the improvement of the sickness are listed. Based on which remedies are going to be mentioned in this part. Various directive remedies which can be used are as follows.

Aβ-directed therapeutics: - Aβ directed therapeutics are researched to attain the intention of decreasing the deposition of the parenchyma Aβ amyloid protein internal the Brain. The amyloid cascade speculation advocate that, accumulation the protein interior the Genius triggers the development of disorder inner the brain, So the remedy which outcomes in decreasing the attention of Aβ protein can substantially enhance the circumstance of the affected person and may additionally decrease the development of disease[68]. In case of Alzheimer disorder related with the deposition of plaques of Aβ amyloid protein can be averted both by using stopping the improvement of plaques interior the brain. Various remedy like Small molecules therapy and β**,** ***γ***-secretase inhibitors or modulators are supposed to be high quality in opposition to AD[69].

SR.NO.	DRUG NAME	EFFECTS
1	2-Amino-4-chlorophenol	Blocks Aβ oligomerization and fibrillization
2	4-Aminophenol	Blocks Aβ oligomerization and fibrillization
3	Resveratrol	Remodels soluble oligomers and amyloid fibrils
4	Coumarin	Inhibits Aβ aggregation
5	Furosemide	Inhibits Aβ oligomerization
6	D737 Inhibits Aβ formation	Inhibits Aβ formation
7	4-Aminoanisole	Blocks Aβ oligomerization and fibrillization
8	3,4-Dihydroxybenzoic acid	Blocks Aβ oligomerization and fibrillization
9	2-Hydroxy-3-ethoxy benzoaldehyde	Blocks Aβ oligomerization and fibrillization
10	ClNQTrp	Inhibits the fibrillization of amyloidogenic proteins

Table.No.4: Summary of inhibitors of amyloid oligomers for the treatment of Alzheimer's disease

Drug Combination Therapy: - Combination remedy consists of use of extra than one therapy or remedy in treatment, mitigation and prevention of disease. Combination cures are noticeably used for a range of disorder such as hypertension, epilepsy, HIV, cognitive coronary heart failure. A combinatorial therapy approach for AD looks extra possibly to yield scientific successes than immunotherapy [70, 71 and 72].The Lilly TRAILBLAZER segment two trials at first examined the aggregate of the BACE1 inhibitor LY3202626 with anti-pyroglutamate Aβ monoclonal antibody donanemab[73]. Unfortunately, LY3202626 used to be discovered to be related with moderate cognitive worsening in committed segment two trials and so the aggregate cure arm was once in the end dropped. Nonetheless, aggregate techniques in scientific trials need to proceed to be encouraged, especially these with mixtures spanning extraordinary drug classes[74].

Conclusion:-

A review on all the studies done for Alzheimer's disease-AD is at a special moment because, even after so many advances in AD pathobiology, etiologic study and therapeutic, we have not recognized a sickness editing remedy that has validated results in human beings. Various biochemical studies, analytical studies and clinical discoveries along genetic, in-vivo, in-vitro and imaging techniques gave us the guide to understand the function of β-amyloid accumulation which initiates infectious basis in humans, and scientific clinical trials carried out have no longer panned out[75].

We have summarized new growth in growing remedies concentrated on β-amyloid and its governing receptors which are responsible for showing neuronal degeneration in brain. Over the world, there are many registered Alzheimer's disorder formulations but they only acts upon the sign and symptoms associated with the disorder, there's no permanent effective drug to stop the degeneration of brain due to Alzheimer's disorder[76]. In the growing world, there were many remedies approved by FDA and authorities in treatment of AD, but all failed to show their important outcomes. The tablets which were manufactured they showed as an inhibitor of β-amlyoid receptors and their dedication of crystal formation plays necessary role in inhibiting and mitigating Alzheimer's disorder. Future scientific trial efforts need to alternatively centre of attention on making use of these anti-amyloid cure techniques to the disease, the before the better, with pills proven to hit their goal effectively. Not solely anti β-amyloid treatment options however additionally Tau and Apo-E directed healing procedures at an early stage has determined to have high-quality doable ahead in therapy of AD. In order to enhance a high quality therapy for AD it is essential to learn about the pathogenesis of disease[77]. In process researches in this place will be important in producing key drugs and ailments that will subsequently expose therapeutic processes main to honestly disease-modifying medications like Alzheimer's disease.

References:-

1. Classification and basic pathology of Alzheimer disease. Duyckaerts C, Delatour B, Potier MC Acta Neuropathol. 2009 Jul; 118(1):5-36 https://pubmed.ncbi.nlm.nih.gov/19381658/
2. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
   McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CHAlzheimers Dement. 2011 May; 7(3):263-9 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312024/
3. Alzheimer's Association (2019). 2019 Alzheimer's disease facts and figures. Alzheimer Dement 15, 321–387
   https://www.alz.org/media/documents/alzheimers-facts-and-figures-2019-r.pdf
4. Naghavi M ,Abajobir ,Abbafati -Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390: 1151-1210 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30403-4/fulltext
5. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.

Lancet. 2017; 390: 1260-1344 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30403-4/fulltext

6. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype
Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, Kern S, Ousset PJ, Maruff P, Skoog I, Verhey FRJ, Freund-Levi Y, Tsolaki M, Wallin ÅK, Olde Rikkert M, Soininen H, Spiru L, Zetterberg H, Blennow K, Scheltens P, Muniz-Terrera G, Visser PJ, Alzheimer Disease Neuroimaging Initiative., AIBL Research Group., ICTUS/DSA study groups Alzheimers Dement. 2019 Jul; 15(7):888-898 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646097/
7. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies Justin M. Long and David M Holtzman https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778042/#R241
8. (Alzheimer's Disease) By Juebin Huang , MD, PhD, Department of Neurology, University of Mississippi Medical Center. https://www.msdmanuals.com/en-in/professional/neurologic-disorders/delirium-and-dementia/alzheimer-disease#v52120767
9. APP processing and synaptic function.Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R.Neuron. 2003 Mar 27; 37(6):925-37. https://pubmed.ncbi.nlm.nih.gov/12670422/
10. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo.Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Neuron. 2008 Apr 10; 58(1):42-51 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2390913/
11. Opposing synaptic regulation of amyloid-β metabolism by NMDA receptors in vivo.Verges DK, Restivo JL, Goebel WD, Holtzman DM, Cirrito JR.J Neurosci. 2011 Aug 3; 31(31):11328-37. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329800/
12. Amyloid beta-protein and lipid metabolism Author links open overlay panel EvaG Zinser Tobias Hartmann Marcus O.W.Grimm https://www.sciencedirect.com/science/article/pii/S0005273607000636
13. The role of tau in Alzheimer's disease and related disorders Rodrigo Medeiros, David Baglietto-Vargas, Frank M LaFerla https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072215/
14. Min S-W, Cho S-H, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, et al. (2010). Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953–966 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035103/
15. Cook C, Carlomagno Y, Gendron TF, Dunmore J, Scheffel K, Stetler C, Davis M, Dickson D, Jarpe M, DeTure M, et al. (2014). Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet. 23, 104–116 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857946/
16. Sohn PD, Tracy TE, Son H-I, Zhou Y, Leite REP, Miller BL, Seeley WW, Grinberg LT, and Gan L (2016). Acetylated tau destabilizes the cytoskeleton in the axon initial

segment and is mislocalized to the somatodendritic compartment. Mol Neurodegener 11-47.

17. Huynh T-PV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, Roh J, Finn MB, Sullivan PM, Esparza TJ, et al. (2017b). Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis. Neuron 96, 1013–1023. e4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728673/

18. Min S-W, Cho S-H, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, et al. (2010). Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953–966 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035103/

19. Min S-W, Cho S-H, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, et al. (2010). Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953–966 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035103/

20. Cook C, Carlomagno Y, Gendron TF, Dunmore J, Scheffel K, Stetler C, Davis M, Dickson D, Jarpe M, DeTure M, et al. (2014). Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet. 23, 104–116 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857946/

21. Sohn PD, Tracy TE, Son H-I, Zhou Y, Leite REP, Miller BL, Seeley WW, Grinberg LT, and Gan L (2016). Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment. Mol Neurodegener 11, 47. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928318/

22. Felsky D, Roostaei T, Nho K, Risacher SL, Bradshaw EM, Petyuk V, Schneider JA, Saykin A, Bennett DA, and De Jager PL (2019). Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. Nat Commun 10, 409. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345810/

23. Roses AD (1996). Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47, 387–400. https://www.ncbi.nlm.nih.gov/pubmed/8712790

24. Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, and Holtzman DM (2014). Altered microglial response to Aβ plaques in APPPS1–21 mice heterozygous for TREM2. Mol Neurodegener 9, 20 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049806/

25. Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, and Holtzman DM (2014). Altered microglial response to Aβ plaques in APPPS1–21 mice heterozygous for TREM2. Mol Neurodegener 9, 20 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049806/

26. Huynh T-PV, Davis AA, Ulrich JD, and Holtzman DM (2017a). Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins. J. Lipid Res. 58, 824–836 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408619/

27. Huynh T-PV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, Roh J, Finn MB, Sullivan PM, Esparza TJ, et al. (2017b). Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis. Neuron 96, 1013–1023. e4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728673/

28. Namba Y, Tomonaga M, Kawasaki H, Otomo E, and Ikeda K (1991). Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541, 163–166.

29. Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, and Holtzman DM (2014). Altered microglial response to Aβ plaques in APPPS1–21 mice heterozygous for TREM2. Mol Neurodegener 9, 20 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049806/

30. Huynh T-PV, Davis AA, Ulrich JD, and Holtzman DM (2017a). Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins. J. Lipid Res. 58, 824–836 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408619/

31. Huynh T-PV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, Roh J, Finn MB, Sullivan PM, Esparza TJ, et al. (2017b). Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis. Neuron 96, 1013–1023. e4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728673/

32. Ryan P, Xu M, Davey AK, Danon JJ, Mellick GD, Kassiou M, and Rudrawar S (2019). O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease. ACS Chem Neurosci 10, 2209–2221 https://pubmed.ncbi.nlm.nih.gov/30985105/

33. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, et al. (1997). Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17, 263–264. https://pubmed.ncbi.nlm.nih.gov/9354781/

34. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, et al. (1999). Apolipoprotein E is essential for amyloid deposition in the APP (V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 96, 15233–15238. https://pubmed.ncbi.nlm.nih.gov/9354781/

35. Bien-Ly N, Gillespie AK, Walker D, Yoon SY, and Huang Y (2012). Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci. 32, 4803–4811. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433173/

36. Kim J, Jiang H, Park S, Eltorai AEM, Stewart FR, Yoon H, Basak JM, Finn MB, and Holtzman DM (2011). Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J. Neurosci. 31, 18007–18012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257514/

37. Kim J, Eltorai AEM, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, and Holtzman DM (2012). Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis. J. Exp. Med. 209, 2149–2156. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501350/

38. Liu C-C, Zhao N, Fu Y, Wang N, Linares C, Tsai C-W, and Bu G (2017). ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron 96, 1024–1032. e3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948105/

39. A Big Step toward a Blood Test for Alzheimer's By Bret Stetka https://www.scientificamerican.com/article/a-big-step-toward-a-blood-test-for-alzheimers/

40. Detecting Alzheimer's Gets Easier with a Simple Blood Test By Esther Landhuis https://www.scientificamerican.com/article/detecting-alzheimers-gets-easier-with-a-simple-blood-test/

41. Better Biomarkers Could Help Us Treat Alzheimer's By Howard M. Fillit https://www.scientificamerican.com/article/better-biomarkers-could-help-us-treat-alzheimers/

42. Alberdi E, Victoria Sanchez-Gomez M, Cavaliere F, Perez-Samartin A, Luis Zugaza J, Trullas R, et al. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 2010; 47: 264–72.

43. De Felice FG, Vieira MN, Saraiva LM, Figueroa-Villar JD, Garcia-Abreu J, Liu R, et al. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J 2004; 18: 1366–72

44. Caruana M, Hogen T, Levin J, Hillmer A, Giese A, Vassallo N. Inhibition and disaggregation of alpha-synuclein oligomers by natural polyphenolic compounds. FEBS Lett 2011; 585: 1113–20

45. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, et al. alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002; 322: 1089–102

46. Visioli F, Poli A, Galli C. Antioxidant and other biological activities of phenols from olives and olive oil. Med Res Rev 2002; 22: 65–75

47. Visioli F, Bellosta S, Galli C. Oleuropein, the bitter principle of olives, enhances nitric oxide production by mouse macrophages. Life Sci 1998; 62: 541–6

48. Andreadou I, Iliodromitis EK, Mikros E, Constantinou M, Agalias A, Magiatis P, et al. The olive constituent oleuropein exhibits antiischemic, antioxidative, and hypolipidemic effects in anesthetized rabbits. J Nutr 2006; 136: 2213–9

49. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, and Holtzman DM (2005). Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48, 913–922. https://pubmed.ncbi.nlm.nih.gov/16364896/

50. Bäuerl C, Collado MC, Diaz Cuevas A, Viña J, and Pérez Martínez G (2018). Shifts in gut microbiota composition in an APP/PSS1 transgenic mouse model of

Alzheimer's disease during lifespan. Lett. Appl. Microbiol. 66, 464–471 https://pubmed.ncbi.nlm.nih.gov/29575030/

51. Huynh T-PV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, Roh J, Finn MB, Sullivan PM, Esparza TJ, et al. (2017b). Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis. Neuron 96, 1013–1023. e4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728673/

52. Jamieson GA, Maitland NJ, Wilcock GK, Yates CM, and Itzhaki RF (1992). Herpes simplex virus type 1 DNA is present in specific regions of brain from aged people with and without senile dementia of the Alzheimer type. J. Pathol. 167, 365–368 https://pubmed.ncbi.nlm.nih.gov/1328575/

53. Huynh T-PV, Davis AA, Ulrich JD, and Holtzman DM (2017a). Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins. J. Lipid Res. 58, 824–836 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408619/

54. Huynh T-PV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, Roh J, Finn MB, Sullivan PM, Esparza TJ, et al. (2017b). Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis. Neuron 96, 1013–1023. e4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728673/

55. Fu Z, Aucoin D, Ahmed M, Ziliox M, Van Nostrand WE, Smith SO. Capping of abeta42 oligomers by small molecule inhibitors. Biochemistry 2014; 53: 7893–903

56. Granic I, Nyakas C, Luiten PGM, Eisel ULM, Halmy LG, Gross G, et al. Calpain inhibition prevents amyloid-beta-induced neurodegeneration and associated behavioral dysfunction in rats. Neuropharmacology 2010; 59: 334–42.

57. Ladiwala ARA, Mora-Pale JM, Dordick JS, Tessier PM. Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways. Abstr Pap Am Chem S 2011; 241

58. Garai K, Sengupta P, Sahoo B, Maiti S. Selective destabilization of soluble amyloid beta oligomers by divalent metal ions. Biochem Biophys Res Commun 2006; 345: 210–5.

59. Scherzer-Attali R, Shaltiel-Karyo R, Adalist YH, Segal D, Gazit E. Generic inhibition of amyloidogenic proteins by two naphthoquinonetryptophan hybrid molecules. Proteins 2012; 80: 1

60. Scherzer-Attali R, Farfara D, Cooper I, Levin A, Ben-Romano T, Trudler D, et al. Naphthoquinone-tyrptophan reduces neurotoxic Abeta*56 levels and improves cognition in Alzheimer's disease animal model. Neurobiol Dis 2012; 46: 663–72.

61. Soto-Ortega DD, Murphy BP, Gonzalez-Velasquez FJ, Wilson KA, Xie F, Wang QA, et al. Inhibition of amyloid-beta aggregation by coumarin analogs can be manipulated by functionalization of the aromatic center. Bioorgan Med Chem 2011; 19: 2596–602

62. Granic I, Nyakas C, Luiten PG, Eisel UL, Halmy LG, Gross G, et al. Calpain inhibition prevents amyloid-beta-induced neurodegeneration and associated behavioral dysfunction in rats. Neuropharmacology 2010; 59: 334–42

63. Zhao W, Wang J, Ho L, Ono K, Teplow DB, Pasinetti GM. Identification of antihypertensive drugs which inhibit Amyloid-beta protein oligomerization. J Alzheimers Dis 2009; 16: 49–57

64. McKoy AF, Chen J, Schupbach T, Hecht MH. A novel inhibitor of amyloid beta (Abeta) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease. J Biol Chem 2012; 287: 38992–9000

65. Godyn J, Jonczyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacol Rep 2016; 68: 127–38.

66. Molecule of the month. Semagacestat. Drug News Perspect 2008; 21: 390

67. Abdul-Hay SO, Sahara T, McBride M, Kang D, Leissring MA. Identification of BACE2 as an avid beta-amyloid-degrading protease. Mol Neurodegen 2012; 7.

68. Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, et al. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun Rev 2008; 7: 391–7

69. Taguchi H, Planque S, Sapparapu G, Boivin S, Hara M, Nishiyama Y, et al. Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. J Biol Chem 2008; 283: 36724–33

70. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat Med 1998; 4: 822–6

71. Arispe N, Pollard HB, Rojas E. Giant multilevel cation channels Formed by Alzheimer-disease Amyloid Beta-Protein [A-Beta-P-(1-40)] in bilayer-membranes. Proc Natl Acad Sci U S A 1993; 90: 10573–7

72. Wang P, Liao W, Fang J, Liu Q, Yao J, Hu M, et al. A glucan isolated from flowers of Lonicera japonica Thunb. Inhibits aggregation and neurotoxicity of Abeta42. Carbohydrate polymers 2014; 110: 142-7

73. 5 Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A 2005; 102: 227–31. 315

74. Diaz JC, Simakova O, Jacobson KA, Arispe N, Pollard HB. Small molecule blockers of the Alzheimer Abeta calcium channel potently protect neurons from Abeta cytotoxicity. Proc Natl Acad Sci U S A 2009; 106: 3348–53

75. Fantini J, Di Scala C, Yahi N, Troadec JD, Sadelli K, Chahinian H, et al. Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer's beta-amyloid peptides. ACS Chem Neurosci 2014; 5: 216–24.

76. Anekonda TS, Quinn JF, Harris C, Frahler K, Wadsworth TL, Woltjer RL. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol Dis 2011; 41: 62–70

77. Min S-W, Cho S-H, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, et al. (2010). Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953–966 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035103/

Figure Legend section:

1. Fig.No.1: Alzheimer’s disease distribution study carried throughout the world based on age and population for both the sexes, 2016
2. Fig.No.2: Prevalence study done at Global levels for Alzheimer's disease and other closely related disorders in both the sexes, 2016
3. Fig.No.3: Global study estimating YLLs and YLDs caused due to Alzheimer's disease and other dementias
4. Fig.No.4: Diagrammatic comparison of Healthy and Alzheimer Diseased Brain
5. Fig.No.5: Diagrammatic representation of comparison of the healthy and diseased Brain
6. Fig.No.6: Representation of formation of α-β Amyloid Protein

Table Legend section:

1. Table.No.1: Tabular representation of the risk of developing disease
2. Table.No.2: Therapeutic strategies for Alzheimer’s disease
3. Table.No.3: Summary of approved drugs for the treatment of Alzheimer's disease
4. Table.No.4: Summary of inhibitors of amyloid oligomers for the treatment of Alzheimer's disease